A growing trend of SC injections heats up competition
By Son, Hyung-Min | translator Kang, Shin-Kook
24.06.13 05:45:00
가나다라
0
Subcutaneous injectable formulations are under development for targeted anticancer agents and ADC, in addition to immunotherapy for cancer
Administration time can be significantly shortened to within 10 minutes…competitions to secure administration convenience have started
Pharmaceutical and biotech companies in Korea and worldwide focus on developing formulation modifications for anticancer agents.
Following 'Tecentriq (atezolizumab)' SC (subcutaneous injection obtaining marketing authorization from the European Medicines Agency (EMA) in January, the R&D of 'Opdivo (nivolumab)' and 'Rybrevant (amivantamab)' is nearing the end.
The industry attributes the recent booming development of SC formulations to their advantages over IV (intravenous) formulations, such as shortened administration time, improved convenience of administration, and reduced injection-related side-effects.
According to the industry sources on June 11th, Bristol Myers Squibb
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)